psalexa
logo

Presbyopia Therapeutics - Pipeline Analysis 2018

Presbyopia Therapeutics - Pipeline Analysis 2018, Clinical Trials & Results, Patents, Designations, Collaborations and Other Developments

Published: January 2018
Report Code: LS11273
Available Format:
Pages: 77

Note: This report can also be updated as of date and delivered within 1-2 workings days of purchase confirmation

Chapter 1. Research Background

1.1 Research Objectives

1.2 Definition

1.3 Research Scope

1.3.1 Pipeline Analysis by Phase

1.3.2 Pipeline Analysis by Molecule Type

1.3.3 Pipeline Analysis by Route of Administration

1.4 Key Stakeholders

Chapter 2. Research Methodology

2.1 Secondary Research

2.2 Primary Research

2.2.1 Breakdown of Primary Research Respondents

2.2.1.1 By industry participant

2.2.1.2 By company type

Chapter 3. Executive Summary

Chapter 4. Pipeline Outlook

4.1 Disease Overview

4.1.1 Theories of Accommodation

4.1.1.1 The Helmholtz theory of accommodation

4.1.1.2 The Schachar theory of accommodation

4.1.1.3 The Coleman theory of accommodation

4.2 Epidemiology

4.3 Classification of Presbyopia

4.4 Sign and Symptoms

4.5 Etiology of Presbyopia

4.6 Prognosis and Follow-up

4.7 Treatment

4.8 Key Drivers

4.8.1 Driver 1

4.8.2 Driver 2

4.9 Key Barriers

4.9.1 Barrier 1

4.9.2 Barrier 2

4.1 Presbyopia Therapeutics Pipeline Analysis

4.10.1 Pipeline Analysis by Phase

4.10.2 Pipeline Analysis by Molecule Type

4.10.3 Pipeline Analysis by Route of Administration

4.10.4 Pipeline Analysis by Company

Chapter 5. Presbyopia Therapeutics Pipeline Analysis by Phase (2018)

5.1 Phase II/III

5.1.1 XXXX

5.1.1.1 Clinical trials

5.1.1.2 Clinical trial results

5.2 Phase II

5.2.1 Oxymetazoline Hydrochloride + Pilocarpine Hydrochloride

5.2.1.1 Clinical trials

5.2.1.2 Clinical trial results

5.2.1.3 Strategic developments

5.2.2 XXXX

5.2.2.1 Clinical trials

5.2.2.2 Clinical trial results

5.2.3 XXXX

5.2.3.1 Clinical trials

5.2.3.2 Clinical trial results

5.2.4 XXX

5.2.4.1 Clinical trials

5.2.4.2 Clinical trial results

5.2.4.3 Patents

5.3 Phase I

5.3.1 EV06 Ophthalmic Solution

5.3.1.1 Clinical trials

5.3.1.2 Clinical trial results

5.3.1.3 Strategic developments

5.4 Pre-Clinical

5.4.1 VP1-001

5.4.1.1 Strategic developments

5.4.2 XXXX

5.5 Discovery

5.5.1 XXXX

5.5.1.1 Strategic developments

Chapter 6. Clinical Trials Review

6.1 Clinical Trials by Region

6.2 Clinical Trials by Trial Status

Chapter 7. Competitive Landscape

7.1 Key Players Benchmarking for Presbyopia Therapeutics Pipeline

7.2 SWOT Analysis of Presbyopia Therapeutics Pipeline

7.2.1 Strengths

7.2.2 Weaknesses

7.2.3 Opportunities

7.2.4 Threats

Chapter 8. Company Profiles

8.1 Allergan Plc.

8.1.1 Business Overview

8.1.2 Product and Service Offerings

8.2 Novartis AG

8.2.1 Business Overview

8.2.2 Product and Service Offerings

8.3 XXXX

8.3.1 Business Overview

8.3.2 Product and Service Offerings

8.4 XXXX

8.4.1 Business Overview

8.4.2 Product and Service Offerings

8.5 XXXX

8.5.1 Business Overview

8.5.2 Product and Service Offerings

8.6 XXXX

8.6.1 Business Overview

8.6.2 Product and Service Offerings

8.7 XXXX

8.7.1 Business Overview

8.7.2 Product and Service Offerings

Chapter 9. Appendix

9.1 Abbreviations

9.1 Related Reports

 

LIST OF TABLES

 

TABLE 1: PIPELINE ANALYSIS OF PRESBYOPIA THERAPEUTICS, BY COMPANY (2018)

TABLE 2: DESCRIPTION OF XXXX

TABLE 3: CLINICAL TRIALS OF XXXX

TABLE 4: DESCRIPTION OF (OXYMETAZOLINE HYDROCHLORIDE + PILOCARPINE HYDROCHLORIDE)

TABLE 5: CLINICAL TRIALS OF (OXYMETAZOLINE HYDROCHLORIDE + PILOCARPINE HYDROCHLORIDE)

TABLE 6: DESCRIPTION OF XXXX

TABLE 7: CLINICAL TRIALS OF XXXX

TABLE 8: DESCRIPTION OF XXXX

TABLE 9: CLINICAL TRIALS OF XXXX

TABLE 10: DESCRIPTION OF XXXX

TABLE 11: CLINICAL TRIALS OF XXXX

TABLE 12: DESCRIPTION OF EV06 OPHTHALMIC SOLUTION

TABLE 13: CLINICAL TRIALS OF EV06 OPHTHALMIC SOLUTION

TABLE 14: DESCRIPTION OF VP1-001

TABLE 15: DESCRIPTION OF XXXX

TABLE 16: DESCRIPTION OF XXXX

TABLE 17: ALLERGAN PLC. - AT A GLANCE

TABLE 18: NOVARTIS AG - AT A GLANCE

TABLE 19: XXXX - AT A GLANCE

TABLE 20: XXXX - AT A GLANCE

TABLE 21: XXXX - AT A GLANCE

TABLE 22: XXXX - AT A GLANCE

TABLE 23: XXXX - AT A GLANCE

 

LIST OF FIGURES

 

FIG 1: RESEARCH METHODOLOGY

FIG 2: SPLIT OF PRIMARY AND SECONDARY RESEARCH

FIG 3: BREAKDOWN OF PRIMARY RESEARCH RESPONDENTS, BY INDUSTRY PARTICIPANT

FIG 4: BREAKDOWN OF PRIMARY RESEARCH RESPONDENTS, BY COMPANY TYPE

FIG 5: PRESBYOPIA IN HUMAN EYE

FIG 6: APPLICATION OF THE HELMHOLTZ THEORY OF ACCOMMODATION IN PRESBYOPIA

FIG 7: APPLICATION OF THE SCHACHAR THEORY OF ACCOMMODATION IN PRESBYOPIA

FIG 8: APPLICATION OF THE COLEMAN THEORY OF ACCOMMODATION IN PRESBYOPIA

FIG 9: PRESBYOPIC SURGICAL METHODS

FIG 10: PRESBYOPIA DRUG CANDIDATES UNDER DEVELOPMENT (2018)

FIG 11: PRESBYOPIA PIPELINE SPLIT, BY MOLECULE TYPE (2018)

FIG 12: BREAKDOWN OF CLINICAL TRIALS, BY REGION

FIG 13: BREAKDOWN OF CLINICAL TRIALS, BY TRIAL STATUS

FIG 14: KEY PLAYERS BENCHMARKING

FIG 15: SWOT ANALYSIS

Place An Order

Single User License
question-mark

The report will be delivered in PDF format without printing rights. It is recommended for a single user.

USD 1850
Group License
question-mark

The report will be delivered in PDF format along with the printing rights. It is recommended for up to five users.

USD 2500
Enterprise License
question-mark

The report will be delivered in PDF format along with printing rights and detailed Excel sheet. It is recommended for organizations where multiple people would like to access the report from multiple locations.

USD 5000

Pre-Purchase Enquiry